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Abstract
Background People with dementia may be particularly
sensitive to cognitive impairment induced by anticholin-
ergic and sedative medicines.
Objective This study aimed to examine if utilisation of
medicines with anticholinergic and sedative effects chan-
ged before and after initiation of anti-dementia therapy.
Methods A retrospective cohort study was conducted
using Australian pharmacy claim data (Pharmaceutical
Benefit Scheme). People with first (index) dispensing for a
cholinesterase inhibitor or memantine between 1 January
2009 and 31 December 2010 who were aged 65 years or
over at the time of initiation were included. The proportion
who received sedatives or anticholinergics in the 6 months
prior to and post initiation of anti-dementia therapy was
determined.
Results The cohort included 24,110 patients, with over
half aged 75-84 years. Overall, 30 % received any class
of anticholinergic or sedative medicine for at least 1 month
in the 6 months prior to initiation of anti-dementia agents,
and 36 % post initiation. Some patients (6 %) ceased an-
ticholinergics or sedatives post initiation even though they
had them in the months prior. However, 12 % commenced
therapy with anticholinergics or sedatives post anti-
dementia therapy initiation even though they were naı¨ve to
them in the 6 months prior to therapy.
Conclusion Medicines with anticholinergic or sedative
effects were commonly dispensed in one-third of people
with dementia. Prescribers need to consider a review of
patients on anticholinergic therapy with cholinesterase in-
hibitors as the effectiveness of the cholinesterase therapy
may be compromised.
Introduction
In 2011, there were 300,000 people with dementia in
Australia, with the number expected to increase to ap-
proximately 900,000 by 2050 [1]. Dementia is a leading
cause of death, and accounted for 6 % of all deaths in
2010 [1]. Alzheimer’s disease (AD) is the most common
form of dementia, accounting for between 50 and 75 % of
all cases [1]. It is a progressive, degenerative illness af-
fecting brain functions. Three cholinesterase inhibitors
(CEIs) are subsidised under the Australian Pharmaceutical
Benefits Scheme (PBS) for the treatment of cognitive
impairment in persons with mild to moderately severe
Alzheimer’s disease: donepezil, galantamine and rivastig-
mine. Memantine, a N-methyl-D-aspartate receptor
(NMDA) inhibitor, is subsidised for people with moder-
ately severe to severe AD.
Many medicines have the potential to impair cognitive
function. A recent literature review found a consistent
correlation between anticholinergic use and cognitive de-
cline (including delirium) in older adults based on findings
from 27 studies [2]. Most studies included in the review
reported that the use of anticholinergics and their burden
was associated with worsening in cognitive performance as
determined by the mini-mental state scores [2]. People with
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dementia undergo progressive cognitive decline due to
damage to the cholinergic neurons system and may be
particularly susceptible to worsening of cognitive function
because of adverse effects caused by anticholinergic and
sedative medicines [3–6]. A study in subjects with Alz-
heimer’s disease reported an average 4-point drop in total
Mini-Mental State Scores in those with positive anti-
cholinergic activity compared to those with negative anti-
cholinergic activity in their serum [7] and worsened
symptoms of dementia, including delusions and halluci-
nations [8]. Moreover, some reports show that anticholin-
ergic activity accelerates Alzheimer’s pathology [9, 10].
Use of multiple anticholinergic medications was found to
be associated with greater risk of hospitalisation for con-
fusion [11].
Medicines with significant anticholinergic effects in-
clude antipsychotics, antidepressants, medicines for uri-
nary incontinence and antihistamines [6, 12, 13]. When
taken concurrently with CEIs, anticholinergics decrease
the effectiveness of CEIs as they have the opposite phar-
macological action (anticholinergics block the action of
acetylcholine in the brain, the amount of which is in-
creased by CEIs to improve the symptoms of dementia)
[14].
Medicines with sedative effects also worsen cognitive
impairment and increase the risk of falls and should be
avoided in people with dementia as the presence of de-
mentia itself increases the risk of falls due to impaired
judgement, gait and balance [15, 16]. Benzodiazepines
and other hypnosedatives, antipsychotics, antidepressants,
antihistamines, opioids and anticonvulsants are examples
of medicines with sedative effects [5, 12]. Many of these
medicines also have anticholinergic properties. Even
though medicines with anticholinergic and sedative ef-
fects should be avoided where possible in people with
dementia [5], past literature suggested their use is com-
mon. A study from the US found that 30 and 34 % of
patients who initiated CEIs received anticholinergics in
the 90 days before and after initiation, respectively [17].
Another US study reported that people with dementia
were more likely to take anticholinergics than matched
controls (33 vs. 23 %, p = 0.001) [18], and a Canadian
study reported 36 % prevalence of anticholinergic pre-
scribing in dementia patients [19]. One Australian study
analysing PBS data from 2006 found that 23 % of CEI
initiators received selected anticholinergic medicines in
the 14 weeks prior to the date of initiation, and 28 %
received them within 14 weeks post initiation [20]. The
studies assessing co-prescription of anticholinergics and
anti-dementia medicines are all more than 5 years old and
the extent to which current practice has changed is not
known.
Aim of the Study
This study aimed to determine current utilisation of
medicines with anticholinergic and sedative effects
amongst people who initiated anti-dementia therapy.
Methods
Study Population
De-identified pharmacy claim data for medicines sub-
sidised and dispensed under the PBS were examined for the
period 2008–2011. Under the PBS, the Australian
Government subsidised the medicine cost above the co-
payment threshold. The co-payment is the amount paid by
the patients towards the cost of their PBS medicines. From
1 January 2012, general patients pay up to $35.40 for most
PBS medicines or $5.80 if they have a concession card.
PBS data is collected from pharmacies and public and
private hospitals. It provides patient information (age,
gender, general/concessional status), as well as prescribing
information (date of supply, drug name, prescribed from,
quantity dispensed, number of repeats). A retrospective
cohort study was undertaken on both concessional and
general patients to determine the extent of dispensing of
sedatives and anticholinergic medicines prior to and post
initiation of CEIs or memantine in this cohort. Patients who
had their first ever (index) CEI or memantine dispensed
between 1 January 2009 and 31 December 2010 and who
were aged 65 years or over at the time of initiation were
included in the cohort. Those who initiated memantine
after initiation of CEIs were excluded. Proportions of the
cohort who were dispensed medicines with sedative or
anticholinergic properties in any one month in the
6 months prior to and including the month of anti-dementia
therapy initiation, as well as in the 6 months post initiation,
were determined. Use or concurrent use with anti-dementia
agents in a month was defined when the use of the
medicine(s) of interest continued for the length of the
whole month (e.g., to have co-dispensing of sedatives and
CEIs, at least one medicine from each group had to be in
use for the whole of the month). Changes in use of anti-
cholinergics and sedatives in the 6 months pre and post
anti-dementia therapy initiation at the level of individual
patients were also assessed.
Medicines Included in the Analyses
Medicines were coded in accordance with the World
Health Organization’s Anatomical Therapeutic Chemical
(ATC) classification system [21].
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Anti-dementia medicines included in the analysis were:
cholinesterase inhibitors—donepezil (N06DA02), rivastig-
mine (N06DA03) and galantamine (N06DA04); NDMA
inhibitors: memantine (N06DX01).
Medicines that are considered clinically important and
are commonly prescribed in the elderly have been
identified by a clinical pharmacist using the Anticholin-
ergic Risk Scale [6] and the Anticholinergic Drug Scale
[13]. The Anticholinergic Risk Scale defines medicines
as having limited or no anticholinergic potential (rating
0), moderate anticholinergic potential (rating 1), strong
anticholinergic potential (rating 2) or very strong anti-
cholinergic potential (rating 3) [6]. The Anticholinergic
Drug Scale rates medicines as level 1 (potentially anti-
cholinergic based on the findings of receptor binding
studies), level 2 (anticholinergic effects sometimes occur,
generally at high doses) and level 3 (markedly anti-
cholinergic) [13]. Medicines rated 0 on the Anticholin-
ergic Risk Scale and level 1 on the Anticholinergic Drug
Scale were excluded due to the low likelihood of these
medicines causing anticholinergic side effects in practice.
When a medication was rated differently on the two
scales, the higher rate was used. Central nervous system-
acting medicines with sedative effects (e.g., opioid
analgesics, antiepileptics, etc.) were identified by a
clinical pharmacist using the Australian Medicines
Handbook and Australian product information for each
medication. Table 1 provides a list of medicines with
sedative and anticholinergic effects included in the study.
For the analysis, these medicines were grouped into six
classes according to their sedative and anticholinergic
effect (Table 2).
Statistical Analysis
McNemar’s test was used to test for differences between
proportions at two time points (e.g., pre-and post compar-
isons) of non-independent samples (subjects from the same
cohort) and p values were reported. Logistic regression was
undertaken to assess the effect of age (gender was not
available in the data for this study) as predictor of the use
of anticholinergics/sedatives concurrently with anti-de-
mentia agents and the odds ratio was reported. Analyses
were performed using the SAS 9.4 statistical package (SAS
Institute, Cary, NC, USA).
Results
The cohort included 24,110 unique patients who initiated
anti-dementia therapy with a CEI or memantine between 1
January 2009 and 31 December 2010. The majority initiated
CEIs (97 %). The age distribution was as follows: 20 %
were aged 65–74 years, 55 % were aged 75–84 years, and
the remaining 25 % were 85 years or over.
Of the 24,110 patients, 7,294 distinct patients (30 %)
had used medicines with anticholinergic or sedative effects
for at least one whole month in the prior 6 months. The
proportion who had received anticholinergics or sedatives
for at least one whole month in the 6-month period post
initiation increased to 36 % (N = 8,610) (p \ 0.0001). A
subgroup of 4,305 unique patients (18 % of all anti-de-
mentia agent initiators) received medicines with anti-
cholinergic properties concurrently with CEI or memantine
for at least one whole month post initiation and another
1,995 unique patients (8 % of all initiators) received
medicines with sedative only (no anticholinergic) proper-
ties concurrently with CEI or memantine. Those who were
aged 85 years or over were more likely to have anti-
cholinergics/sedatives co-dispensed with anti-dementia
agents compared to those under 85 years of age (Odds
Ratio = 1.09, 95 % CI 1.02, 1.16, p = 0.016).
Medicines with anticholinergic or sedative properties
were dispensed to between 17 and 20 % of the cohort in
each month of the 6 months prior to and at the time of anti-
dementia therapy initiation, with the overall use stabilising
at around 22 % in each month post initiation (Fig. 1). In
the first month immediately after anti-dementia medicine
initiation, 15 % of patients were dispensed anticholinergic
or sedative medicines concurrently with anti-dementia
medicines, decreasing to 8 % at month six (p \ 0.0001),
(Fig. 1). At 1 month post initiation of the dementia medi-
cine, 7 % of patients received anticholinergics or sedatives
but were no longer on the anti-dementia medicine, in-
creasing to 14 % by month six (p \ 0.0001) (Fig. 1). The
remaining patients either had no therapy at all (neither anti-
dementia therapy nor anticholinergics nor sedatives—26 %
at month one increasing to 51 % by month six,
p \ 0.0001), or continued to receive anti-dementia therapy
but no anticholinergics or sedatives (52 % at month one
decreasing to 27 % by month six, p \ 0.0001).
Figure 2 presents the subsidised anticholinergics and
sedatives dispensed to the cohort of initiators stratified by
the class of those medicines. The figure shows that 70 % of
the patients who initiated anti-dementia therapy did not
receive subsidised medicines with anticholinergic or
sedatives effect prior to initiation—the majority (58 % of
the full cohort) continued not to have those medicines after
initiation of a CEI or memantine;, however, 12 % com-
menced them post initiation even though they were naı¨ve in
the months prior. Only 6 % stopped anticholinergic and
sedative therapy post initiation even though they had had it
prior to initiation.
Comparison of prior with post anticholinergic/sedative
therapy by class shows that most of the patients continued
to receive the same class or classes of medicines. For
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example, medicines with a sedative effect were dispensed to
10 % of the patients prior to therapy, and to 10.8 % post
therapy (p \ 0.0001). A combination of two or more classes
was dispensed to 7 % prior to therapy, and to 6.8 % post
therapy (p = 0.167). Highly anticholinergic and sedative
medicines were received for at least 1 month by 4.6 % prior
to therapy, and by 4.0 % post therapy (p \ 0.0001).
Moderately anticholinergic and sedative medicines were
dispensed to 3.5 % prior to therapy, increasing to 6.7 %
post therapy (p \ 0.0001). Moderately anticholinergic
Table 1 Rating of medicines with sedative or anticholinergic effects
ATC code, medicine Rating ATC code, Medicine Rating
Antispasmodics and antidiarrhoeals Antypsychotics
N05AA01 Chlorpromazine S, A3A03AB05 Propantheline A3
A03BA01 Atropine A3 N05AB04 Prochlorperazine S, A2
A03FA01 Metoclopramide A1 N05AB06 Trifluoperazine S, A3
A07DA03 Loperamide A2 N05AC01 Pericyazine S, A3
Antiarrhythmics and antihypertensives N05AD01 Haloperidol S, A2
N05AE04 Ziprasidone S, A2C01BA03 Disopyramide A2
C02AB01 Methyldopa S Atypical antipsychotics
C02AC01 Clonidine S N05AH03 Olanzapine S, A3
Drug for urinary incontinence N05AH04 Quetiapine S, A2
N05AL05 Amisulpride SG04BD04 Oxybutynin A3
Muscle relaxants N05AX08 Risperidone S, A2
M03BX01 Baclofen S, A2 N05AX12 Aripiprazole S
N05AX13 Paliperidone S, A2
Opioids Benzodiazepines
N02AA01 Morphine S N05BA01 Diazepam S
N02AA03 Hydromorphone S N05BA04 Oxazepam S
N02AA05 Oxycodone S N05BA08 Bromazepam S
N02AA59 Codeine/paracetamol S N05BA12 Alprazolam S
N02AB03 Fentanyl S N05CD02 Nitrazepam S
N02AC04 Dextropropoxyphene S N05CD03 Flunitrazepam S
N02AE01 Buprenorphine S N05CD07 Temazepam S
N02AX02 Tramadol S Non-benzodiazipine hypnotics
Antiepileptics N05CF01 Zopiclone S
N03AA02 Phenobarbital S N05CF02 Zolpidem S
N03AA03 Primidone S Antidepressants
N03AB02 Phenytoin S N06AA02 Imipramine S, A3
N03AE01 Clonazepam S N06AA04 Clomipramine S, A3
N03AF01 Carbamazepine S, A2 N06AA09 Amitriptyline S, A3
N03AG01 Valproate S N06AA10 Nortriptyline S, A3
N03AG04 Vigabatrin S N06AA12 Doxepin S, A3
N03AX09 Lamotrigine S N06AA16 Dothiepin S, A3
N03AX11 Topiramate S N06AB05 Paroxetine A2
N03AX12 Gabapentin S N06AX03 Mianserin S
N03AX16 Pregabalin S N06AX11 Mirtazapine S
Anti-parkinsonian drugs Broncholidators
N04AA01 Benzhexol S, A3 R03BB01 Ipratropium A2
N04AA02 Biperiden A3 R03BB04 Tiotropium A2
N04AC01 Benzatropine A3 Antihistamines
N04BB01 Amantadine A2 R06AD02 Promethazine S, A3
R06AX02 Cyproheptadine S, A3
S sedative effect, A1 limited anticholinergic activity, A2 moderately anticholinergic, A3 highly anticholinergic
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drugs were dispensed to 3.5 % prior to therapy, and to
3.3 % post therapy (p = 0.050)—the inhaled medications
ipratropium and tiotropium accounted for most of the use;
however, their overall prevalence was low. Highly anti-
cholinergic medicines were dispensed to 1.4 % prior to
therapy and to 1.3 % post therapy (p = 0.105), with oxy-
butinin being the most commonly used.
Antidepressants were dispensed to 12 % of the cohort
prior to anti-dementia therapy initiation and the proportion
stayed the same (12 %) post initiation (p = 0.057). Mir-
tazapine, amitriptyline and paroxetine were the most
commonly dispensed antidepressants. Antipsychotics were
received by 10 % of the cohort prior to and by 16 % post
initiation (p \ 0.0001), with risperidone, olanzapine and
quetiapine most commonly used (all atypical antipsy-
chotics). Benzodiazepines were dispensed to 17 % of the
cohort prior to and 18 % post initiations (p \ 0.0001), with
temazepam, oxazepam and diazepam most commonly
used.
Discussion
In this study 30 % of the cohort received any class of
anticholinergic or sedative medicine for at least 1 month in
the 6 months prior to initiation of anti-dementia agents,
increasing significantly to 36 % post initiation. Our results
are very similar to a US study reporting that 30 and 34 %
of patients who initiated CEIs received anticholinergics in
the 90 days before and after initiation, respectively [17].
An earlier Australian study analysing PBS data from 2006
and using a limited number of medicines with anthi-
cholinergic properties found that 23 % of CEI initiators
received selected anticholinergic medicines in the
14 weeks prior to the date of initiation, and 28 % received
them within 14 weeks post initiation [20]. Our results are
slightly higher; however, we included additional medicines
with anticholinergic and sedative properties.
Overall, 26 % received anticholinergics/sedatives con-
currently with CEI or memantine for at least 1 month in the
Table 2 Classes of sedative
and anticholinergic medicines
Class Abbreviation in the results
presentation
Inclusion criteria
Medicines with sedative effect Sed Any medicine from Table 1
with S rating
Highly anticholinergic and sedative
medicines
HighAS Any medicine from Table 1
with S, A3 rating
Moderately anticholinergic and sedative
medicines
ModAS Any medicine from Table 1
with S, A2 rating
Highly anticholinergic medicines HighA Any medicine from Table 1
with A3 rating
Moderately anticholinergic medicines ModA Any medicine from Table 1
with A2 rating
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6 months post the date of initiation, with those aged
85 years and over more likely to receive co-medications.
The consequences to a patient of having medicines with an
anticholinergic effect that oppose the action of CEIs have
been stated elsewhere [14]. At any 1-month time point, our
analysis showed that around one in five patients who ini-
tiated anti-dementia therapy received medicines with an-
ticholinergic or sedative effect prior to initiation. In the
month immediately after initiation, 15 % received anti-
cholinergic or sedative medicines concurrently with the
anti-dementia agents, with this proportion decreasing to
8 % at 6 months post initiation. However, the proportion of
subjects who discontinued their anti-dementia medicines
but received anticholinergics or sedatives increased by an
equivalent 7 % from month one to month six, implying a
stable monthly use of anticholinergics or sedatives over the
6-month period. Medicines with anticholinergic properties
have been associated with a decline in cognitive functions
in elderly people, including a decline in visual impairment,
confusion, poor verbal and semantic memory, and de-
creased executive functions [3, 4, 22]. Older people with
dementia may be particularly susceptible to cognitive de-
cline (especially of memory) induced by medicines with an
anticholinergic and sedative effect [5–8]. Reducing the
number of those medicines may improve cognitive func-
tion and reduce the likelihood of adverse events [5]. Fur-
ther, reduction of use prior to initiation of therapy may be
necessary to determine patient response to therapy. One
French study found an increase in the risk of incident de-
mentia over a 4-year follow-up period in continuous users
of anticholinergic medicines (hazard ratio 1.65, 95 % CI
1.00–2.73) [23]. A second French study found that even
though consistent users of anticholinergics had poorer
cognitive performance at 8 years’ follow-up, this did not
increase the risk of developing dementia; however, the
study may have been under-powered for the dementia
endpoint [24].
Use of medicines with highly anticholinergic and
sedative effects decreased slightly after initiation (4.6 %
prior to vs. 4.0 % post), while use of medicines with
moderate anticholinergic and sedative effects increased
significantly after initiation (3.5 % prior to vs. 6.7 % post).
Antidepressants were used by 12 % of the cohort prior to
and post initiation. This is lower than the 22 % prevalence
of depression and mood affective disorders in people with
dementia in Australia in 2009 [25]; however, we only
analysed antidepressants with anticholinergic effects. The
use of antipsychotics increased significantly post initiation
of anti-dementia therapy (from 10 % prior to therapy to
16 % post therapy). Risperidone, quetiapine and olan-
zapine were found to be commonly prescribed both in the
earlier Australian study [20] and in our study. The higher
use of atypical antipsychotics might relate to their use for
treatment of behavioural and psychological symptoms
Fig. 2 Anticholinergic/sedative
use prior and post initiation of
anti-dementia therapy—by class
(as defined in Table 2). No
therapy denotes no use of
medicines with anticholinergic
and/or sedative effect in any
month prior to or post initiation;
Comb denotes use of more than
one class of sedatives and/or
anticholinergics over the
6 months prior to or post
initiation; Sed, HighAS, etc.
denote use of the specific class
only, for at least 1 month prior
to/post initiation. The post
therapy percentages do not add
up to 100 as therapies with use
in below 0.5 % of the patients
are omitted in the figure
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associated with dementia; however, these medicines have
shown only a small beneficial effect and should be used for
a limited time [26, 27]. Oxybutynin is likely to be pre-
scribed to control urinary incontinence, which can also be
an adverse effect of CEIs. The overall prevalence of the
inhaled medications ipratropium and tiotropium was low;
besides, they are expected to have a low likelihood of
systemic absorption. Results from the current study re-
confirm that even though medicines with anticholinergic
and sedative effects should be avoided in people with de-
mentia, they are continuing to be commonly dispensed.
We analyzed data from a national dataset capturing
prescription data of all Australians. A limitation is that
some medicines with anticholinergic or sedative effects
were under co-payment for general patients and were not
available in the PBS dataset [28]. However, the majority of
patients of age 65 years or over have concession status and
thus the number of missed prescriptions is assumed to be
low. Some over-the-counter products also have anti-
cholinergic properties which may have an additive effect to
those in the prescribed medicines. No data on these
medicines is available for this study. We used a conser-
vative approach for dispensing and co-dispensing where
people had to be co-prescribed medicines for each day in
the month to be considered co-administered therapies. This
may underestimate the actual proportion of concurrent use
where shorter durations of co-administration occurred.
Conclusion
Medicines with anticholinergic or sedative effects were
commonly dispensed amongst people with dementia, with
one-third receiving them at some time in the 6 months
prior to and post initiation of anti-dementia agents. While
concurrent use with anti-dementia medicines did decrease
over time, one in six patients was prescribed CEIs and
anticholinergics or sedatives in the month after CEI ini-
tiation. Some patients (6 %) ceased anticholinergic or
sedative medicines post initiation even though they had
them in the months prior to initiation. However, 12 %
commenced anticholinergics or sedatives post anti-de-
mentia therapy initiation, even though they were naı¨ve to
them in the months prior to the therapy. Prescribers need to
consider reviewing patients on anticholinergic therapy with
CEIs as the effectiveness of the cholinesterase therapy may
be compromised.
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